Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORZORA: Olaparib Maintenance in Ovarian Cancer
NCT02476968Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, open-label trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival up to 55 months. Started Sep 2015; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02476968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476968.